BDF Gestion Has $6.53 Million Stake in Intuitive Surgical, Inc. $ISRG

Key Points

• BDF Gestion reduced its stake in Intuitive Surgical by 5.9%, now holding 12,022 shares valued at approximately $6.53 million.
• Intuitive Surgical reported a 21.4% revenue increase year-over-year for the latest quarter, with earnings per share of $2.19, exceeding expectations.
• Institutional investors own 83.64% of Intuitive Surgical, with notable increases in holdings from firms like Vanguard Group and Wellington Management.

BDF Gestion reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 5.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,022 shares of the medical equipment provider's stock after selling 752 shares during the quarter. Intuitive Surgical comprises about 0.7% of BDF Gestion's investment portfolio, making the stock its 27th biggest position. BDF Gestion's holdings in Intuitive Surgical were worth $6,533,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Norway Savings Bank increased its holdings in Intuitive Surgical by 53.4% in the 2nd quarter. Norway Savings Bank now owns 2,613 shares of the medical equipment provider's stock valued at $1,420,000 after purchasing an additional 910 shares in the last quarter. Trust Co. of Oklahoma acquired a new stake in Intuitive Surgical in the 2nd quarter valued at $363,000. Neville Rodie & Shaw Inc. increased its holdings in Intuitive Surgical by 11.9% in the 2nd quarter. Neville Rodie & Shaw Inc. now owns 10,427 shares of the medical equipment provider's stock valued at $5,666,000 after purchasing an additional 1,110 shares in the last quarter. Arlington Trust Co LLC increased its holdings in Intuitive Surgical by 34.5% in the 1st quarter. Arlington Trust Co LLC now owns 745 shares of the medical equipment provider's stock valued at $369,000 after purchasing an additional 191 shares in the last quarter. Finally, Mogy Joel R Investment Counsel Inc. increased its holdings in Intuitive Surgical by 1.2% in the 2nd quarter. Mogy Joel R Investment Counsel Inc. now owns 68,678 shares of the medical equipment provider's stock valued at $37,320,000 after purchasing an additional 840 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Intuitive Surgical

In related news, insider Gary S. Guthart sold 29,360 shares of the firm's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $472.49, for a total value of $13,872,306.40. Following the completion of the transaction, the insider owned 19,827 shares of the company's stock, valued at approximately $9,368,059.23. This trade represents a 59.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Amy L. Ladd sold 336 shares of the firm's stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $470.11, for a total transaction of $157,956.96. Following the completion of the transaction, the director directly owned 1,074 shares of the company's stock, valued at approximately $504,898.14. This trade represents a 23.83% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,224 shares of company stock valued at $21,716,492. Corporate insiders own 0.70% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Erste Group Bank restated a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Intuitive Surgical in a research note on Friday, August 22nd. BTIG Research raised their target price on Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. UBS Group raised their target price on Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $615.00 target price on shares of Intuitive Surgical in a research note on Tuesday, August 19th. Thirteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Trading Up 0.7%

Shares of ISRG stock traded up $3.32 during trading hours on Tuesday, hitting $447.87. 1,384,733 shares of the company were exchanged, compared to its average volume of 2,045,193. The business has a 50 day moving average of $475.20 and a two-hundred day moving average of $502.92. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00. The company has a market capitalization of $160.55 billion, a PE ratio of 62.47, a PEG ratio of 4.60 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same quarter in the prior year, the firm earned $1.78 earnings per share. The firm's revenue was up 21.4% compared to the same quarter last year. On average, research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.